Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

02 Jun 2026 - 04 Jun 2026
17 Jun 2026 - 19 Jun 2026

First-Ever Medical Technology Regrows Nerves and Stops Amputations in Diabetic Patients

By HospiMedica International staff writers
Posted on 06 Oct 2025

Chronic wounds are among the most devastating and costly complications for diabetic and trauma patients, often leading to severe infections, tissue death, and amputations. More...

Despite the global wound care market exceeding USD 22 billion, existing treatments such as wound vacs, grafts, and antimicrobial creams only manage symptoms rather than addressing underlying nerve and circulation damage. Now, a new regenerative medical technology can restore nerve function, heal tissue, and prevent amputations in patients once deemed untreatable.

Developed by Rapid Nexus (Brea, CA, USA), the patented device is the first medical technology proven to regenerate nerves and reverse chronic wounds. Unlike other products that just protect the tissue, this technology, adapted to treat advanced wounds, uses a top-down approach that rebuilds the surrounding tissue and then works its way back into the bed of the wound.

It works by targeting the root cause of tissue death — damaged nerve and vascular networks — restoring blood flow and tissue vitality from within. The approach goes beyond surface healing by combining nerve regeneration and improved circulation in a single treatment system, making it the first of its kind to actively repair rather than manage chronic wounds.

In a 2018 feasibility study, every patient previously diagnosed for amputation and treated with the technology successfully avoided limb loss. One case involved a 32-year-old diabetic mother whose leg had begun to turn necrotic; after treatment, nerve regeneration and restored blood flow allowed her to walk again.

The most recent peer-reviewed study, scheduled for publication this fall, reports dozens of biomarkers working simultaneously to trigger nerve and vascular regeneration — an outcome described as unprecedented in wound healing research. The device is currently completing FDA review and has entered clinical trials with commercial rollout expected by late 2025, thus expanding its use to hospitals, home care, and underserved regions worldwide.

“We could apply this healing approach to the whole body — and prevent countless amputations that were once seen as inevitable,” said Dr. Margaret Kalmeta, founder of Rapid Nexus. “This is about restoring human dignity, one limb at a time.”

Related Links:
Rapid Nexus


Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
12-Channel ECG
CM1200B
New
Blood Pressure Monitor
Cuff Blood Pressure Monitor
New
Fetal Monitor
BT-380
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The Elyra TFL System uses thulium fiber laser technology for efficient stone dusting and reduced stone migration, with an air-cooled design for quieter, more compact operation (photo courtesy of BD

BD Launches Elyra Laser Platform for Kidney Stone and Soft Tissue Procedures

BD (Becton, Dickinson and Company) has introduced the Elyra Thulium Fiber Laser (TFL) System, an advanced laser platform developed to complete its kidney stone care portfolio for urology teams.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.